---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-212548"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:25:49.158491+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q2 net loss $34.9M; restructures with 35% workforce cut

## Summary
- Cash, equivalents, marketable securities $703.8M as of June 30, 2022; runway through 2028.
- R&D expense $28.9M (up 106% YoY), G&A $8.9M (up 39% YoY) on higher headcount and stock comp.
- Phase 1 monotherapy dosing underway for BET inhibitor NUV-868 in advanced solid tumors.
- Appointed Dr. David Liu as CMO (July) and Kerry Wentworth as CRO (May) to Executive Committee.
- Restructuring announced Aug 1, reducing workforce by 35% to cut costs and align with re-prioritized pipeline.

## SEC filing metadata
- accession: 0001193125-22-212548
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312522212548/0001193125-22-212548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312522212548/d312793d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-212548
- JSON: https://secwatch.observer/filing/0001193125-22-212548.json
- Plain text: https://secwatch.observer/filing/0001193125-22-212548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.